Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | 30 Months Ended | 36 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 27, 2026 |
Sep. 28, 2025 |
Sep. 27, 2026 |
Sep. 28, 2025 |
Sep. 27, 2026 |
Sep. 27, 2026 |
|||||||||
| Restructuring charges/(credits): | ||||||||||||||
| Employee terminations | $ 702 | $ 124 | $ 1,071 | $ 360 | ||||||||||
| Asset impairments | 30 | 111 | 112 | 328 | ||||||||||
| Exit costs | 21 | 2 | 38 | 96 | ||||||||||
| Restructuring charges/(credits) | [1] | 753 | 237 | 1,221 | 784 | |||||||||
| Transaction costs | 2 | 0 | 2 | 0 | ||||||||||
| Integration costs and other | [2] | 35 | 49 | 124 | 162 | |||||||||
| Restructuring charges and certain acquisition-related costs | 791 | 286 | 1,347 | 945 | ||||||||||
| Inventory write-offs––recorded in Cost of sales | 6 | 33 | 52 | 33 | ||||||||||
| Additional depreciation––asset restructuring recorded in condensed consolidated statements of operations | [3] | 14 | 4 | 28 | 11 | |||||||||
| Implementation costs | [4] | 131 | 105 | 364 | 234 | |||||||||
| Total costs associated with acquisitions and cost-reduction/productivity initiatives | 940 | 423 | 1,788 | 1,150 | ||||||||||
| Biopharma [Member] | ||||||||||||||
| Restructuring charges/(credits): | ||||||||||||||
| Restructuring charges/(credits) | 461 | 240 | 882 | 451 | ||||||||||
| Biopharma [Member] | Manufacturing Optimization Program [Member] | ||||||||||||||
| Restructuring charges/(credits): | ||||||||||||||
| Restructuring charges/(credits) | 65 | 117 | 14 | (295) | $ 889 | |||||||||
| Biopharma [Member] | Realigning Our Cost Base Program [Member] | ||||||||||||||
| Restructuring charges/(credits): | ||||||||||||||
| Restructuring charges/(credits) | 385 | 107 | 849 | 669 | $ 3,700 | |||||||||
| Income Statement Location [Axis]: us-gaap:CostOfGoodsAndServicesSold | ||||||||||||||
| Restructuring charges/(credits): | ||||||||||||||
| Additional depreciation––asset restructuring recorded in condensed consolidated statements of operations | [3] | 14 | 3 | 27 | 10 | |||||||||
| Implementation costs | [4] | 21 | 26 | 61 | 72 | |||||||||
| Income Statement Location [Axis]: us-gaap:OtherNonoperatingIncomeExpense | ||||||||||||||
| Restructuring charges/(credits): | ||||||||||||||
| Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net | (1) | (6) | (3) | (74) | ||||||||||
| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost | ||||||||||||||
| Restructuring charges/(credits): | ||||||||||||||
| Additional depreciation––asset restructuring recorded in condensed consolidated statements of operations | [3] | 0 | 1 | 0 | 1 | |||||||||
| Implementation costs | [4] | 60 | 53 | 162 | 116 | |||||||||
| Income Statement Location [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | ||||||||||||||
| Restructuring charges/(credits): | ||||||||||||||
| Implementation costs | [4] | $ 50 | $ 26 | $ 142 | $ 46 | |||||||||
| ||||||||||||||